{"analyses":[{"groupDescription":"Change in SI from BL to W12","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.021","pValueComment":"Significant at p\\<0.05","statisticalMethod":"t-test, 2 sided","testedNonInferiority":false},{"groupDescription":"Change in SD from BL to W12","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"Significant at p\\<0.05","statisticalMethod":"t-test, 2 sided","testedNonInferiority":false},{"groupDescription":"Change in SI from BL to W12","groupIds":["OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0228","pValueComment":"Significant at p\\<0.05","statisticalMethod":"t-test, 2 sided","testedNonInferiority":false},{"groupDescription":"Change in SD from BL to W12","groupIds":["OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"Significant at p\\<0.05","statisticalMethod":"t-test, 2 sided","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.9","value":"1.2"},{"groupId":"OG001","spread":"0.8","value":"1.4"}]}],"title":"SI (BL)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.0","value":"1.3"},{"groupId":"OG001","spread":"0.7","value":"1.2"}]}],"title":"SI (W4)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.7","value":"0.9"},{"groupId":"OG001","spread":"0.6","value":"1.0"}]}],"title":"SI (W12)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.1","value":"2.9"},{"groupId":"OG001","spread":"0.8","value":"2.9"}]}],"title":"SD (BL)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.1","value":"2.4"},{"groupId":"OG001","spread":"1.0","value":"2.1"}]}],"title":"SD (W4)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.1","value":"2.0"},{"groupId":"OG001","spread":"1.1","value":"1.9"}]}],"title":"SD (W12)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"30"}],"units":"Participants"}],"description":"Cancer Rehabilitation Evaluation System (CARES) Sexual Dysfunction (SD) and Sexual Interest (SI) Subscales range from 0 to 4 and measure the severity of problems, with higher scores indicating more difficulty.","dispersionType":"Standard Deviation","groups":[{"description":"Estring 2mg ring inserted vaginally once every 12 weeks","id":"OG000","title":"Estring"},{"description":"Testosterone Cream 1% micronized in velvachol - 0.5 gm of cream vaginally each night for two weeks, then 3 times a week for total of 12 weeks of treatment","id":"OG001","title":"Testosterone Cream"}],"paramType":"MEAN","populationDescription":"Participants who provided responses to SD, SI and SS at 3 time points: Baseline (BL), Week 4 (W4), and Week 12 (W12)","reportingStatus":"POSTED","timeFrame":"Baseline, Week 4, Week 12","title":"Sexual Quality of Life","type":"SECONDARY","unitOfMeasure":"units on a scale"}